person · Reporting owner
Konstantinov Konstantin
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Chief Technology Officer | March 28, 2023 | March 30, 2023 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Codiak BioSciences, Inc.
Report date March 28, 2023 · Filed March 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,932 |
Reported balance
After 2023-03-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-28 · Sale · Disposed 7,432 · Balance 1,932 F1: Includes an aggregate of 1,932 shares of common stock acquired on June 30, 2022 and December 30, 2022 under the Issuer's Employee Stock Purchase Plan (ESPP). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-28 · Sale · Disposed 1,932 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 1,932 shares of common stock acquired on June 30, 2022 and December 30, 2022 under the Issuer's Employee Stock Purchase Plan (ESPP).
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,889 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 3,889 F1: Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228897 · ownership.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228897 · ownership.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,889 F1 · shares: Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 15, 2025 Filed May 20, 2025 00:26 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,800 | $0.00 Strike: $123.26 | $0.00 |
DisclosureSEC source: 0000950170-25-074761 · ownership.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 15, 2025 Filed May 20, 2025 00:26 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 973 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074761 · ownership.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,894 F1 · shares: Mr. Konstantinov was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:27 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,376 | $0.00 Strike: $171.03 | $0.00 |
DisclosureSEC source: 0000950170-24-062614 · ownership.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,376 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:27 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 701 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062614 · ownership.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,921 F1 · shares: Mr. Konstantinov was awarded 701 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:19 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,487 | $0.00 Strike: $156.63 | $0.00 |
DisclosureSEC source: 0000899243-23-013665 · doc4.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487 Underlying: Common Stock · 1,487 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:19 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013665 · doc4.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,220 F1 · shares: Mr. Konstantinov was awarded 686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 18, 2024, one year from the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:13 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,932 | $0.20 | $386.40 |
DisclosureSEC source: 0000950170-23-011029 · ownership.xml · nonDerivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:13 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 7,432 | $0.20 | $1,487.14 |
DisclosureSEC source: 0000950170-23-011029 · ownership.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,932 F1 · balance_after: Includes an aggregate of 1,932 shares of common stock acquired on June 30, 2022 and December 30, 2022 under the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,391 | $0.59 | $823.75 |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · nonDerivative · entry 4 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,432 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · derivative · entry 6 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 4,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F4 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 4,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · nonDerivative · entry 3 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 16:15 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000899243-23-002755 · doc4.xml · derivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-23 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 16:36 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,069 | $0.58 | $614.89 |
DisclosureSEC source: 0000899243-23-002402 · doc4.xml · nonDerivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,731 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 16:36 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002402 · doc4.xml · derivative · entry 3 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 2,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On January 19, 2022, the reporting person was granted 8,400 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On January 19, 2022, the reporting person was granted 8,400 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 16:36 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 2,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-002402 · doc4.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 16:15 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031586 · doc4.xml · derivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023. F2 · derivative.expiration_date: On September 16, 2022, the reporting person was granted 80,000 restricted stock units, vesting on June 30, 2023. Read SEC document |
| August 17, 2022 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,308 | $2.21 | $2,894.47 |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · nonDerivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,623 F2 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| August 16, 2022 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionRestricted Stock Units · Derivative | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · derivative · entry 5 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 4,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F4 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| August 16, 2022 Filed Feb 21, 2023 16:32 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 4,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-005696 · doc4.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,498 | $0.00 Strike: $159.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020283 · doc4.xml · derivative · entry 3 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,498 Underlying: Common Stock · 2,498 shares Expires 2032-05-26 F3 · derivative.exercise_date: The shares vest in equal annual instalments over a three-year period with each such vesting date occurring on the earlier of the anniversary of the grant date or the date of the annual meeting of the Company's shareholders of the applicable year of such three-year period. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,298 | $0.00 Strike: $159.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020283 · doc4.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 1,298 shares Expires 2032-05-26 F2 · derivative.exercise_date: Award vests in full on May 26, 2023, one year from grant date. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:23 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 534 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020283 · doc4.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534 F1 · shares: Mr. Konstantinov was awarded 534 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 26, 2023, one year from the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007004 · doc4.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 16,800 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F3 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 16,800 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 11,200 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000899243-22-007004 · doc4.xml · derivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Common Stock · 11,200 shares Expires 2032-02-15 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantRestricted Stock Units · Derivative | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-002861 · doc4.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0000899243-22-002861 · doc4.xml · derivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 08, 2021 Filed Sep 28, 2021 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,276 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-21-038063 · doc4.xml · derivative · entry 4 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,978 Underlying: Common Stock · 7,276 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions. F5 · derivative.exercise_date: The shares underlying this option are fully vested. Read SEC document |
| June 08, 2021 Filed Sep 28, 2021 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 1,004 | $26.04 | $26,145.67 |
DisclosureSEC source: 0000899243-21-038063 · doc4.xml · nonDerivative · entry 3 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions. F2 · kind: The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.00 to $26.12 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2021 Filed Sep 28, 2021 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | SaleCommon Stock | 6,272 | $25.53 | $160,130.43 |
DisclosureSEC source: 0000899243-21-038063 · doc4.xml · nonDerivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004 F1 · date: The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions. F2 · kind: The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $25.00 to $25.99 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2021 Filed Sep 28, 2021 16:05 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | Exercise / conversionCommon Stock | 7,276 | $3.29 | $23,938.04 |
DisclosureSEC source: 0000899243-21-038063 · doc4.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 16:52 UTC | Codiak BioSciences, Inc. CDAK · Entity 114958 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $26.60 | $0.00 |
DisclosureSEC source: 0000899243-21-003317 · doc4.xml · derivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-01-21 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 22, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.